Please login to the form below
Ubrelvy
This page shows the latest Ubrelvy news and features for those working in and with pharma, biotech and healthcare.
Biohaven gets FDA approval for migraine drug Nurtec ODT
The new drug’s approval by the FDA follows the agency’s green light for Allergan’s Ubrelvy (ubrogepant) in December. ... That is slightly lower than the $4, 896 annual list price for Ubrelvy, according to ICER.
Latest news
-
Lundbeck gets US approval for migraine drug at heart of Alder takeover
The product category has extended with an orally-active CGRP drug in December when Allergan secured FDA approval for Ubrelvy (ubrogepant), though this isn’t a direct competitor as it is
-
Botox strength bolsters Allergan ahead of AbbVie takeover
Allergan chief executive Brent Saunders said Allergan is entering 2020 with “strong momentum”, helped by approvals such as an FDA green light for new acute migraine therapy Ubrelvy (ubrogepant).
-
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Its closest competitor is Allergan’s Ubrelvy (ubrogepant) – an oral CGRP inhibitor which also has FDA approval in the treatment of acute migraine, with or without aura.
-
Allergan gets FDA nod for first oral CGRP drug for migraine
The US regulator has given a green light to Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the ... Atogepant is expected to account for the bulk of Allergan’s sales
-
Allergan’s oral migraine drug closer to US filing
New data keeps Allergan ahead of rival Biohaven
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed in the acute treatment setting, rimegepant will also have to beat competitors like Reyvow and Ubrelvy, both of which are also oral drugs with very attractive profiles. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
